RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)
Clinical trials for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL) trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test 'One-Two Punch' to make Cancer-Killing cell therapy last longer
Disease control Recruiting nowThis study is for people with a hard-to-treat type of aggressive B-cell lymphoma that has come back or hasn't responded to other treatments. Researchers want to see if giving two additional drugs (chidamide and a PD-1 inhibitor) as maintenance therapy after a person's own immune …
Matched conditions: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)
Phase: PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New 'Armored' immune cell therapy tested for Tough-to-Treat blood cancer
Disease control Recruiting nowThis early-stage study is testing the safety and best dose of a new type of CAR-T cell therapy for adults whose diffuse large B-cell lymphoma has come back or not responded to other treatments. The therapy uses the patient's own modified immune cells, which are engineered to targ…
Matched conditions: RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)
Phase: PHASE1 • Sponsor: Jiangsu Topcel-KH Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC